Regulating advanced therapy medicinal products through the Hospital Exemption: an analysis of regulatory approaches in nine EU countries

Research output: Contribution to journalJournal articleResearchpeer-review

  • Delphi G. M. Coppens
  • Helga Gardarsdottir
  • Marie L. De Bruin
  • Pauline Meij
  • Hubert G. M. Leufkens
  • Jarno Hoekman

Aim: To study regulatory approaches for the implementation and utilization of the Hospital Exemption (HE) in nine EU countries. Materials & methods: Using public regulatory documentation and interviews with authorities we characterized the national implementation process of the HE, including national implementation characteristics and two outcomes: national licensing provisions and the amount of license holders. Results: National licensing provisions vary substantially among selected countries as a result of different regulatory considerations that relate to unmet medical needs, benefit/risk balance, and innovation. The amount of license holders per country is moderate (0-11). Conclusion: The HE facilitates HE utilization in clinical practice in some countries, yet safeguarding of public health and incentivizing commercial development is challenging.

Original languageEnglish
JournalRegenerative Medicine
Volume15
Issue number8
Pages (from-to)2015-2028
Number of pages14
ISSN1746-0751
DOIs
Publication statusPublished - Aug 2020

    Research areas

  • advanced therapy medicinal product, clinical practice, commercial development, drug regulatory science, hospital exemption, implementation process, license holders, national licensing provisions, REGENERATIVE MEDICINE, EUROPEAN-UNION, MEMBER STATES, CELL, LEGISLATION, CHALLENGES, TRANSPOSITION, ADOPTION, FUTURE, ACCESS

ID: 271639616